P023  Secondary membranous nephropathy in a patient with a background of rheumatoid arthritis treated with biosimilar etanercept

Conclusion This is the case of an 80-year-old gentleman who developed membranous nephropathy eight months after commencing etanercept biosimilar - Benepali® - for rheumatoid arthritis. Although attribution to a single agent is challenging, we believe that it is likely Benepali® was the main attributing fa ctor for the development of membranous nephropathy. The temporal relationship between the initiation of Benepali® and the subsequent development of biopsy proven membranous nephropathy along with the resolution following withdrawal of Benepali® supports drug-related renal injury. Although TNF inhi bitor-induced renal injury is uncommon, this case highlights the need for physicians to maintain a high level of suspicion if a patient on a TNF inhibitor, including biosimilars, develops proteinuria and renal injury.Disclosure L. Sammut: None.T. Leach: None.L. Yalakki: None.
Source: Rheumatology - Category: Rheumatology Source Type: research